tocilizumab

1.	Woodworth, Thasia: 2 articles (10/2008 - 03/2008)
2.	Alecock, Emma: 2 articles (10/2008 - 03/2008)
3.	Uchiyama, Yasushi: 2 articles (06/2008 - 06/2008)
4.	Mihara, Masahiko: 2 articles (06/2008 - 06/2008)
5.	Ohsugi, Yoshiyuki: 2 articles (05/2008 - 12/2005)
6.	Kishimoto, Tadamitsu: 2 articles (05/2008 - 03/2008)
7.	Mori, Masaaki: 2 articles (03/2008 - 06/2005)
8.	Imagawa, Tomoyuki: 2 articles (03/2008 - 06/2005)
9.	Miyamae, Takako: 2 articles (03/2008 - 06/2005)
10.	Yokota, Shumpei: 2 articles (03/2008 - 06/2005)

Related Diseases

1.	Rheumatoid Arthritis 11/01/2008 - "CONCLUSIONS: Tocilizumab represents a promising new treatment for rheumatoid arthritis" 08/01/2008 - "Interlukin-6 receptor inhibitor tocilizumab: a new treatment option in rheumatoid arthritis?" 06/01/2008 - "Tocilizumab has been assessed in a number of studies in recent years, mainly in patients with rheumatoid arthritis" 01/01/2007 - "Tocilizumab has been assessed in a number of studies in recent years, mainly in patients with rheumatoid arthritis (RA)" 08/01/2008 - "PURPOSE: The pharmacology, pharmacokinetics, clinical efficacy, safety, and role of tocilizumab in rheumatoid arthritis (RA) are reviewed" Get all the results and reference details, order at left...
2.	Crohn Disease (Crohn's Disease) 12/01/2006 - "Besides Castleman's disease and RA, tocilizumab has been shown to be effective for patients with soJIA and Crohn's disease" 01/01/2008 - "Tocilizumab is expected to ameliorate the autoimmune inflammatory diseases with IL-6 overproduction and has been clinically developed as a therapeutic agent for RA, systemic-onset and articular types of JIA, Crohn's disease, etc. Tocilizumab has been shown to be effective not only for improving signs and symptoms but also for preventing joint destruction of RA" 05/01/2006 - "RECENT FINDINGS: The safety and efficacy of tocilizumab have been demonstrated in clinical trials conducted in patients with rheumatoid arthritis and other autoimmune inflammatory diseases, such as juvenile idiopathic arthritis and Crohn's disease" 11/01/2006 - "Blocking IL-6 actions by use of a humanized antibody, tocilizumab, which targets the IL-6 receptor, has been proven to be therapeutically effective for rheumatoid arthritis, systemic juvenile idiopathic arthritis, Castleman disease and Crohn's disease" 09/01/2006 - "Tocilizumab (namely MRA), a humanized anti-interleukin (IL)-6 receptor monoclonal antibody, is under development by Roche for the treatment of inflammatory autoimmune diseases such as rheumatoid arthritis (RA), systemic onset juvenile idiopathic arthritis (JIA), adult-onset Still's disease, Castleman's disease and Crohn's disease" Get all the results and reference details, order at left...
3.	Juvenile Rheumatoid Arthritis (Juvenile Idiopathic Arthritis) 03/22/2008 - "INTERPRETATION: Tocilizumab is effective in children with systemic-onset juvenile idiopathic arthritis" 08/01/2008 - "In the trial of tocilizumab in systemic-onset juvenile idiopathic arthritis, the primary end-point in the open-label lead-in was the proportion of subjects achieving an American College of Rheumatology Pediatric 30 response and 91% of subjects had achieved this at 6 weeks" 03/22/2008 - "Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial." 06/01/2005 - "Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis." 11/01/2008 - "Is tocilizumab a good therapeutic option for RA and systemic-onset juvenile idiopathic arthritis?" Get all the results and reference details, order at left...
4.	Giant Lymph Node Hyperplasia (Castleman's Disease) 01/01/2007 - "This is the first report on tocilizumab efficacy for Castleman's disease after approval for use for Castleman's disease." 05/10/2007 - "Effectiveness of humanized anti-interleukin-6 receptor antibody (tocilizumab) for Castleman's disease mainly with pulmonary involvement]" 01/01/2007 - "We report three cases of multicentric Castleman's disease (MCD) successfully treated with anti-interleukin-6 receptor antibody (tocilizumab)" 01/01/2007 - "Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease." 08/01/2006 - "Effectiveness of long term administration of humanized anti-interleukin-6 receptor antibody (tocilizumab) for multicentric Castleman's disease with pulmonary involvement]" Get all the results and reference details, order at left...
5.	Inflammation 06/01/2005 - "After a few cases of compassionate use of tocilizumab, phase I and II studies of tocilizumab were conducted in children with sJIA, revealing that tocilizumab abruptly reduced the typical symptoms of inflammation and improved laboratory abnormalities" 04/01/2008 - "We successfully administered Tocilizumab to stabilize the inflammation, and inflammatory symptoms and signs of the patients were abruptly gone" Get all the results and reference details, order at left...
30 Diseases and 45 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Interleukin-6 (Interleukin 6)
2.	Methotrexate (Mexate)
3.	Interleukin-6 Receptors (Interleukin 6 Receptor)
4.	C-Reactive Protein
5.	Hemoglobins (Hemoglobin)
6.	Antirheumatic Agents (DMARD)
7.	abatacept (BELATACEPT)
8.	Simvastatin (Zocor)
9.	Sodium
10.	Immunoglobulins (Immunoglobulin)
215 Drugs and Important Bio-Agents and 26 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Stents
2 Therapies and Procedures and 4 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>